New hope for advanced ovarian cancer: triple-drug combo before surgery plus maintenance therapy

NCT ID NCT05952453

Recruiting now Disease control Sponsor: University of Alabama at Birmingham Source: ClinicalTrials.gov ↗

First seen Mar 13, 2026 · Last updated May 20, 2026 · Updated 12 times

Summary

This study tests a combination of three drugs (carboplatin, paclitaxel, and pembrolizumab) given before surgery to shrink tumors in people with newly diagnosed stage III or IV ovarian cancer. After surgery, participants receive more chemotherapy plus two maintenance drugs (olaparib and pembrolizumab) to help keep the cancer from coming back. The goal is to see if this approach improves how long people live without their cancer progressing.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Locations

O'Neal Comprehensive Cancer Center at UAB
RECRUITING

Birmingham, Alabama, 35294, United States

Contact Email: •••••@•••••

Contact

Conditions

Explore the condition pages connected to this study.

OVARIAN CANCER